These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33909097)

  • 1. Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.
    Grechko N; Skarbova V; Tomaszewska-Kiecana M; Ramlau R; Centkowski P; Drew Y; Dziadziuszko R; Zemanova M; Beltman J; Nash E; Habeck J; Liao M; Xiao J
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):259-270. PubMed ID: 33909097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of absorption, distribution, metabolism, and excretion of [
    Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
    Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.
    Shapiro GI; Kristeleit RS; Burris HA; LoRusso P; Patel MR; Drew Y; Giordano H; Maloney L; Watkins S; Goble S; Jaw-Tsai S; Xiao JJ
    Clin Pharmacol Drug Dev; 2019 Jan; 8(1):107-118. PubMed ID: 29799676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
    Slingerland M; Hess D; Clive S; Sharma S; Sandstrom P; Loman N; Porro MG; Mu S; Waldron E; Valera SZ; Gelderblom H
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1089-98. PubMed ID: 25253045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors.
    Green ML; Ma SC; Goble S; Giordano H; Maloney L; Simmons AD; Beltman J; Harding TC; Xiao JJ
    Cancer Chemother Pharmacol; 2022 May; 89(5):671-682. PubMed ID: 35397664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
    Liao M; Beltman J; Giordano H; Harding TC; Maloney L; Simmons AD; Xiao JJ
    Clin Pharmacokinet; 2022 Nov; 61(11):1477-1493. PubMed ID: 36107395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
    Mu S; Lin C; Skrzypczyk-Ostaszewicz A; Bulat I; Maglakelidze M; Skarbova V; Andreu-Vieyra C; Sahasranaman S
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):81-88. PubMed ID: 33772633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment.
    Rolfo C; Isambert N; Italiano A; Molife LR; Schellens JHM; Blay JY; Decaens T; Kristeleit R; Rosmorduc O; Demlova R; Lee MA; Ravaud A; Kopeckova K; Learoyd M; Bannister W; Locker G; de Vos-Geelen J
    Br J Clin Pharmacol; 2020 Sep; 86(9):1807-1818. PubMed ID: 32227355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
    Dal Molin GZ; Westin SN; Coleman RL
    Future Oncol; 2018 Dec; 14(30):3101-3110. PubMed ID: 30105925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
    Shibata SI; Chung V; Synold TW; Longmate JA; Suttle AB; Ottesen LH; Lenz HJ; Kummar S; Harvey RD; Hamilton AL; O'Neil BH; Sarantopoulos J; LoRusso P; Rudek MA; Dowlati A; Mulkerin DL; Belani CP; Gandhi L; Lau SC; Ivy SP; Newman EM
    Clin Cancer Res; 2013 Jul; 19(13):3631-9. PubMed ID: 23653147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10.
    Drew Y; Kristeleit RS; Oaknin A; Ray-Coquard I; Haris NM; Swisher EM
    Oncologist; 2020 Jan; 25(1):e109-e119. PubMed ID: 31575788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer.
    Moore DC; Ringley JT; Patel J
    J Pharm Pract; 2019 Apr; 32(2):219-224. PubMed ID: 29166829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
    Liao M; Jeziorski KG; Tomaszewska-Kiecana M; Láng I; Jasiówka M; Skarbová V; Centkowski P; Ramlau R; Górnaś M; Lee J; Edwards S; Habeck J; Nash E; Grechko N; Xiao JJ
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):887-897. PubMed ID: 34370076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline
    Kristeleit R; Shapiro GI; Burris HA; Oza AM; LoRusso P; Patel MR; Domchek SM; Balmaña J; Drew Y; Chen LM; Safra T; Montes A; Giordano H; Maloney L; Goble S; Isaacson J; Xiao J; Borrow J; Rolfe L; Shapira-Frommer R
    Clin Cancer Res; 2017 Aug; 23(15):4095-4106. PubMed ID: 28264872
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
    Lorusso D; Maltese G; Sabatucci I; Cresta S; Matteo C; Ceruti T; D'Incalci M; Zucchetti M; Raspagliesi F; Sonetto C; Sinno V; Ronzulli D; Giolitto S; de Braud F
    Target Oncol; 2021 Jan; 16(1):59-68. PubMed ID: 33369704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance.
    Lorusso D; García-Donas J; Sehouli J; Joly F
    Target Oncol; 2020 Jun; 15(3):391-406. PubMed ID: 32495160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed,
    Kristeleit RS; Oaknin A; Ray-Coquard I; Leary A; Balmaña J; Drew Y; Oza AM; Shapira-Frommer R; Domchek SM; Cameron T; Maloney L; Goble S; Lorusso D; Ledermann JA; McNeish IA
    Int J Gynecol Cancer; 2019 Nov; 29(9):1396-1404. PubMed ID: 31685558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.
    Rolfo C; de Vos-Geelen J; Isambert N; Molife LR; Schellens JHM; De Grève J; Dirix L; Grundtvig-Sørensen P; Jerusalem G; Leunen K; Mau-Sørensen M; Plummer R; Learoyd M; Bannister W; Fielding A; Ravaud A
    Clin Pharmacokinet; 2019 Sep; 58(9):1165-1174. PubMed ID: 30877569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.
    Xiao JJ; Nowak D; Ramlau R; Tomaszewska-Kiecana M; Wysocki PJ; Isaacson J; Beltman J; Nash E; Kaczanowski R; Arold G; Watkins S
    Clin Transl Sci; 2019 Jan; 12(1):58-65. PubMed ID: 30427584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
    Wang DD; Li C; Sun W; Zhang S; Shalinsky DR; Kern KA; Curtin NJ; Sam WJ; Kirkpatrick TR; Plummer R
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):89-98. PubMed ID: 27128213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.